Magnesium Sulfate (Magnesium Sulfate) Patent Expiration, LOE Window & CMS Spending

Magnesium Sulfate (Magnesium Sulfate) by Fresenius Kabi: Off-Patent Genericized (AB Competition), 8 AB generics, $20.5M 2024 CMS Part D & Medicaid spend, and 17 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFresenius Kabi
FDA Application & PathwayN019316 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$20.5M
2024 Medicare Part D Spend$174K
2024 Medicaid Spend$20.3M
Reported Wholesale Price Change (CA SB 17)17 WAC filings (max 173.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.